Chair of the BIE Board since 2025.

Alan is the President and Chief Scientific Officer of NodThera, a biotech focused on the discovery of inhibitors of the NLRP3 inflammasome. He has 40 years’ experience in pharmaceutical and biotech R&D, both in the UK and in the US, specialising in the fields of inflammation, neuroscience and metabolism. In 2016 he led the formation and startup of the biotech NodThera and has discovered and developed clinical stage novel NLRP3 inflammasome inhibitors for the treatment of cardiometabolic and neurodegenerative diseases.  

Alan served on the Board of the Babraham Institute from 2012 to 2017 as a Non-Executive Director before joining the Board of Babraham Institute Enterprise in 2017 and taking over as Chair in 2025.